Detection of Peritoneal Micrometastasis in Gastric and Pancreatic Cancer in Peritoneal Wash Samples
NCT00582062 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144
Last updated 2023-05-06
Summary
We are undertaking a study of patients with gastric or pancreatic cancer. A common place for cancer to return after surgery for gastric or pancreatic cancer is the inside lining of the abdomen, called "peritoneal metastasis". At the time of surgery, washing the abdomen with a mild salt solution may reveal free cancer cells in the abdomen which could develop into peritoneal metastasis. Recently, surgeons here at Memorial Sloan-Kettering have found that patients who have these cells develop peritoneal metastases and are better treated with chemotherapy rather than surgery. Sometimes, though, these cells might be present but cannot be found by using current techniques. We are trying to figure out a better way to find these free cancer cells. This could improve our treatment of patients with gastric and pancreatic cancer. We need "negative control" population to which we can compare the peritoneal washings of these cancer patients.
Conditions
- Gastric and Pancreatic Cancer
Interventions
- OTHER
-
washings for experimental marker testing
During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Daniel Coit, MD · Memorial Sloan Kettering Cancer Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-03-31
- Primary Completion
- 2023-05-02
- Completion
- 2023-05-02
Countries
- United States
Study Locations
More Related Trials
-
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
NCT04929015 ·Status: SUSPENDED ·Phase: NA
-
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482 ·Status: COMPLETED
-
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347 ·Status: WITHDRAWN
-
HIPEC for Peritoneal Carcinomatosis
NCT02040142 ·Status: COMPLETED ·Phase: PHASE2
-
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802 ·Status: RECRUITING
-
In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer
NCT05842187 ·Status: UNKNOWN ·Phase: NA
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
NCT06200376 ·Status: RECRUITING ·Phase: PHASE1
-
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
NCT04858009 ·Status: RECRUITING ·Phase: PHASE2
-
Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer
NCT00559598 ·Status: COMPLETED
-
Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer
NCT02517268 ·Status: COMPLETED ·Phase: NA
-
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
NCT02570711 ·Status: TERMINATED ·Phase: PHASE2
-
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
NCT00068432 ·Status: COMPLETED ·Phase: PHASE2
-
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
NCT05216120 ·Status: WITHDRAWN ·Phase: PHASE2
-
Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
NCT00826982 ·Status: COMPLETED
-
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
NCT06662006 ·Status: RECRUITING ·Phase: PHASE2
-
Role of Perfusion CT in Pancreatic Cancer
NCT01703650 ·Status: UNKNOWN
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05034627 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Pancreatic Adenocarcinoma Gene Environment Risk Study
NCT00912717 ·Status: RECRUITING
-
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
NCT00265876 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Predicting Effective Therapy in Pancreatic Cancer
NCT03033927 ·Status: ACTIVE_NOT_RECRUITING
-
Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity
NCT03821870 ·Status: COMPLETED
-
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726 ·Status: COMPLETED ·Phase: PHASE2
-
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003 ·Status: COMPLETED
-
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
NCT01458717 ·Status: COMPLETED ·Phase: PHASE2/PHASE3